Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Monte Rosa Therapeutics Inc (GLUE)

Monte Rosa Therapeutics Inc (GLUE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street Motley Fool - Tue Jan 16, 8:00AM CST

Analysts have high hopes for these three innovation companies in 2024.

BEAM : 22.57 (-2.08%)
EWTX : 18.38 (-5.16%)
GLUE : 3.59 (-8.88%)
Wall Street - shutterstock_1321462400
Pre-Market Brief: Stocks Climb As Investors Await FOMC Minutes Barchart - Tue Jan 3, 2023

March S&P 500 futures (ESH23) are trending up +1.12% this morning after three major U.S. benchmark indices closed lower on 2022’s last trading day as market participants braced for the new year with...

ESH23 : 3,957.05s (-0.09%)
LI : 19.45 (+1.94%)
NIO : 4.53 (+2.03%)
TSLA : 231.26 (+10.20%)
FMS : 19.16 (-0.05%)
GLUE : 3.59 (-8.88%)
Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates Globe Newswire - Thu Aug 11, 2022

– Submitted Investigational New Drug (IND) Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader for the Treatment of Myc-driven Solid Tumors...

GLUE : 3.59 (-8.88%)
Monte Rosa Therapeutics Reports First Quarter 2022 Financial Results and Business Updates Globe Newswire - Wed May 11, 2022

– Presented Preclinical Data at AACR Annual Meeting Supporting Clinical Development of MRT-2359 as Potent and Selective GSPT1-directed Molecular Glue...

GLUE : 3.59 (-8.88%)
Monte Rosa Therapeutics Presents Preclinical Data Highlighting Potential of GSPT1-directed Molecular Glue Degrader MRT-2359 to Target Myc-driven Cancers at AACR Annual Meeting 2022 Globe Newswire - Fri Apr 8, 2022

– Data Highlight Essential Role of GSPT1 in Sustaining Myc-induced Translational Addiction in Solid Tumors – BOSTON, April 08, 2022 (GLOBE NEWSWIRE) --...

GLUE : 3.59 (-8.88%)
Monte Rosa Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates Globe Newswire - Tue Mar 29, 2022

– Company on Track for Mid-year Filing of Investigational New Drug (IND) Application for Lead Candidate MRT-2359 – – Progressed NEK7 and CDK2 Molecular...

GLUE : 3.59 (-8.88%)
Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences Globe Newswire - Thu Feb 3, 2022

BOSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader...

GLUE : 3.59 (-8.88%)
Monte Rosa Therapeutics and Yeda, the commercial arm of the Weizmann Institute of Science, Announce License and Research Collaboration to Accelerate Discovery of Novel Covalent Molecular Glue Degraders Globe Newswire - Tue Jan 25, 2022

BOSTON and REHOVOT, Israel, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel...

GLUE : 3.59 (-8.88%)
Monte Rosa Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference Globe Newswire - Tue Jan 4, 2022

BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader...

GLUE : 3.59 (-8.88%)
Monte Rosa Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer Globe Newswire - Thu Dec 2, 2021

BOSTON, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader...

GLUE : 3.59 (-8.88%)

Barchart Exclusives

3 Top-Rated Dividend Kings Trading Near Their 52-Week Lows Barchart - 17 minutes ago
These quality companies all have something in common: They are trading a little off their 52-week lows and pay an ever-increasing dividend. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot